Chemistry:Zamicastat

From HandWiki

Zamicastat (INN; developmental code name BIA-5-1058) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which is under development for the treatment of pulmonary arterial hypertension (PAH) and heart failure.[1][2] It is structurally related to etamicastat and is said to be an improved version of this drug.[2] As of July 2022, zamicastat is in phase 2 clinical trials for PAH and phase 1 clinical trials for heart failure.[1] However, no recent development has been reported for heart failure.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 "Zamicastat". 28 July 2022. https://adisinsight.springer.com/drugs/800033043. 
  2. ↑ 2.0 2.1 "Dopamine β hydroxylase as a potential drug target to combat hypertension". Expert Opin Investig Drugs 29 (9): 1043–1057. September 2020. doi:10.1080/13543784.2020.1795830. PMID 32658551. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Zamicastat&oldid=4177465"